Clinical use of proteasome inhibitors in the treatment of multiple myeloma

Clinical use of proteasome inhibitors in the treatment of multiple myeloma

Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved prote...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2014-12, Vol.8 (1), p.1-20
Hauptverfasser: Merin, Noah M, Kelly, Kevin R
Format: Artikel
Sprache:eng
Schlagworte:
Cancer therapies
Multiple myeloma
Pharmacology
Protease inhibitors
proteasome inhibitors
Review
Toxicity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph8010001